Related Experiment Video

Updated: Oct 29, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.1K

Fingerprint loss during combination therapy using osimertinib and anlotinib: A case report

Lijiao Xie1, Yongdong Feng1, Jianguo Sun1

  • 1Cancer Institute, Xinqiao Hospital, Army Medical University, Chongqing, China.

Journal of Clinical Pharmacy and Therapeutics
|July 9, 2021
PubMed
Abstract

Insights

Combination therapy for advanced non-small-cell lung cancer (NSCLC) using osimertinib and anlotinib can cause fingerprint loss. This side effect resolved upon anlotinib discontinuation, highlighting a potential adverse event in EGFR-mutated NSCLC treatment.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • EGFR inhibitors combined with VEGFR TKIs show improved efficacy in EGFR-mutated advanced NSCLC.
  • Investigating adverse effects of combination therapy is crucial.

Observation:

  • A patient with EGFR-mutated advanced NSCLC developed fingerprint loss.
  • This occurred during treatment with osimertinib (EGFR TKI) and anlotinib (multi-target TKI).

Findings:

  • Fingerprint loss resolved after discontinuing anlotinib.
  • The symptom recurred upon re-initiation of anlotinib, suggesting a causal link.

Implications:

  • This is the first reported case of fingerprint loss with osimertinib and anlotinib combination therapy.
  • Clinicians should be aware of this potential side effect in NSCLC patients receiving this regimen.
Keywords:
EGFR mutationanlotinibfingerprint lossnon-small-cell lung cancerosimertinib

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.3K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.3K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K